| Cancer therapeutics and mechanisms | Lifetime | 36 | US 24 | 99.67 |
| Cancer Treatment and Pharmacology | Lifetime | 116 | US 66 | 99.60 |
| Neutropenia and Cancer Infections | Lifetime | 55 | US 33 | 99.30 |
| Pharmacogenetics and Drug Metabolism | Lifetime | 109 | US 60 | 99.05 |
| Cancer Genomics and Diagnostics | Lifetime | 338 | US 199 | 99.35 |
| Economic and Financial Impacts of Cancer | Lifetime | 67 | US 46 | 98.81 |
| Lung Cancer Research Studies | Lifetime | 210 | US 105 | 99.10 |
| Pharmaceutical studies and practices | Lifetime | 131 | US 74 | 98.60 |
| Colorectal Cancer Treatments and Studies | Lifetime | 268 | US 124 | 99.11 |
| Neonatal Health and Biochemistry | Lifetime | 170 | US 97 | 98.21 |
| Lung Cancer Treatments and Mutations | Lifetime | 532 | US 254 | 98.83 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 523 | US 245 | 98.61 |
| Statistical Methods in Clinical Trials | Lifetime | 123 | US 62 | 97.90 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 940 | US 425 | 98.02 |
| Drug Transport and Resistance Mechanisms | Lifetime | 687 | US 279 | 97.33 |
| HER2/EGFR in Cancer Research | Lifetime | 522 | US 239 | 97.86 |
| Renal cell carcinoma treatment | Lifetime | 713 | US 369 | 97.21 |
| Ethics in Clinical Research | Lifetime | 263 | US 154 | 95.44 |
| Antibiotics Pharmacokinetics and Efficacy | Lifetime | 911 | US 307 | 96.37 |
| Biomedical Ethics and Regulation | Lifetime | 211 | US 113 | 94.79 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 590 | US 321 | 95.71 |
| Chronic Myeloid Leukemia Treatments | Lifetime | 933 | US 389 | 96.24 |
| Chemical Reactions and Isotopes | Lifetime | 523 | US 268 | 95.06 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 741 | US 318 | 89.17 |
| Biosimilars and Bioanalytical Methods | Lifetime | 961 | US 358 | 88.73 |
| Berberine and alkaloids research | Lifetime | 823 | US 113 | 80.58 |
| Chemotherapy-related skin toxicity | Lifetime | 934 | US 406 | 79.44 |
| Pharmaceutical industry and healthcare | Lifetime | 896 | US 509 | 79.81 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 232 | US 149 | 93.26 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 871 | US 282 | 93.54 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 837 | US 345 | 92.06 |
| Chronic Myeloid Leukemia Treatments | 2021-2025 | 461 | US 204 | 91.64 |
| Pharmacogenetics and Drug Metabolism | 2021-2025 | 182 | US 66 | 89.22 |
| Statistical Methods in Clinical Trials | 2021-2025 | 215 | US 88 | 87.88 |
| Pharmaceutical studies and practices | 2021-2025 | 330 | US 116 | 86.01 |
| Biomedical Ethics and Regulation | 2021-2025 | 152 | US 62 | 84.72 |
